A share price of Candel Therapeutics Inc [CADL] is currently trading at $4.95, down -4.26%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CADL shares have gain 12.63% over the last week, with a monthly amount drifted -43.94%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Candel Therapeutics Inc [NASDAQ: CADL] stock has seen the most recent analyst activity on February 20, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $25. Previously, Canaccord Genuity started tracking the stock with Buy rating on February 19, 2025, and set its price target to $20. On February 07, 2025, BofA Securities initiated with a Buy rating and assigned a price target of $15 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $11 on December 02, 2022. BMO Capital Markets initiated its recommendation with a Outperform and recommended $18 as its price target on November 19, 2021. UBS started tracking with a Buy rating for this stock on August 23, 2021, and assigned it a price target of $9. In a note dated August 23, 2021, Jefferies initiated an Buy rating and provided a target price of $22 on this stock.
Candel Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $3.79 and $14.60. Candel Therapeutics Inc [NASDAQ: CADL] shares were valued at $4.95 at the most recent close of the market.
Analyzing the CADL fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.52, Equity is -4.69 and Total Capital is -0.48. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.82 points at the first support level, and at 4.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.17, and for the 2nd resistance point, it is at 5.40.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Candel Therapeutics Inc [NASDAQ:CADL] is 2.77. Further, the Quick Ratio stands at 2.77, while the Cash Ratio is 2.74.
Transactions by insiders
Recent insider trading involved Nichols William Garrett, Chief Medical Officer, that happened on Mar 18 ’25 when 45316.0 shares were sold. Chief Scientific Officer, Barone Francesca completed a deal on Mar 18 ’25 to sell 32146.0 shares. Meanwhile, Chief Executive Officer Tak Paul Peter sold 25772.0 shares on Mar 18 ’25.
